No Data
No Data
No Data
No Data
No Data
Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024
SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos"), a clinical stage biopharmaceutical company focused on developing novel therapeutic
GlobeNewswireApr 9 08:00 ET
Express News | Aligos Therapeutics Announces First Subjects Dosed In Phase 2a HERALD Study Of ALG-055009 In MASH Subjects
Moomoo 24/7Apr 3 08:18 ET
Mirum's LIVMARLI Receives Positive Reimbursement Recommendation by Canada's CADTH
Seeking AlphaApr 2 08:59 ET
Express News | Earlier Announced, Aligos Therapeutics Has Been Awarded A $1.3M NIH Contract To Conduct Clinical Development Of A Compound For The Treatment Of Covid-19
Moomoo 24/7Apr 1 11:31 ET
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 From ALG-055009 and ALG-000184 Phase 1 Studies
SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos"), a clinical stage biopharmaceutical company focused on developing novel therapeutic
GlobeNewswireMar 27 08:00 ET
Express News | Aligos Therapeutics Announces Initiation Of Phase 2a HERALD Study Of ALG-055009 In MASH Subjects
Moomoo 24/7Mar 18 08:01 ET
No Data
No Data